We are not financial engineers but company builders. We align with our founders on the journey and have a proven track-record of supporting our companies by leveraging our relationships to build teams, attract customers, raise investment and deliver exits. We are active partners that get our hands dirty to help our companies succeed.
The most important element for us is people. We look for world-class teams and founders that are the best at what they do and know what they don’t know.
We look for unfair advantages, whether that be proprietary technology, protected IP, unique proposition, contrarian thinking, initial partnerships and a stellar team.
We take a concentrated portfolio approach to drive discipline in our selection and to enable us to work alongside founders in a meaningful way. Our approach is honest, challenging but respectful. We’re aligned in helping you build a business over the long term and do not believe in financial engineering, taking fees or telling you what you want to hear.
Luminous Ventures is a London-based VC advisor investing in Deep Tech ventures with a focus on the application of artificial intelligence (AI), VR, AR, edge computing, robotics, quantum technologies and synthetic biology to healthcare, life science, nutrition, food and agriculture at Seed and Series A in Europe and North America. Since the inception of our first fund in 2015, we have deployed over £25 million in disruptive, deep-tech businesses.
Key team members
Isabel Fox is a mother, wellness coach, Peloton enthusiast and one of just a handful of female General Partners in the UK. Prior to founding Luminous Ventures, Isabel was head of Venture Capital at White Cloud Capital where she focused on early stage investments in life sciences and healthcare. With a background in investment banking and private equity turnarounds, Isabel founded and exited two corporate communications firms focused on the route to exit, co-founded two software start-ups (one exit) and been an active angel investor in the UK and US. She has worked in New York, San Francisco and London. At Luminous Ventures, Isabel has the opportunity to invest in visionary founders with breakthrough technologies, and backing deep-tech and science that matters.
Max was previously a healthcare and life science investor at White Cloud Capital, making venture and growth capital investments in Europe and Asia across a range of indications, technologies and services. Having graduated from the University of Cambridge, Max started out as a corporate lawyer at Slaughter and May in London, Milan and Tokyo, sitting in the TMT and IP group. There he worked on, among other things, technology IPOs and M&A, giving him a taste for the commercial and investment side. His experience in intellectual property and regulation is particularly useful for the deep technology companies in which Luminous invests. Outside of the office, Max is often to be found trail running in the mountains or (where he can't get away) the Surrey Hills.
Peter is a scientist discovering the potential of technology to disrupt traditionally siloed and deeply technical scientific industries. Despite his pivot away from his background in therapeutics, he still appraises deep technology platforms with the same rigour common to the biopharma industry. Whilst the inflections in deep tech may be different to therapeutics, a commitment to quality science, a thorough understanding of the patient or customer need, and a clear capital efficient plan to execute are commonalities. He currently works in corporate strategy at Synthace, and before this was working in healthcare investment roles and with deep technology start-up accelerators. He has a DPhil in Chemical Biology from Oxford University, a master’s in chemistry (top of year) from Warwick Uni and experience in biopharma R&D. Outside of work, Peter is a huge animal lover, his favourite animals being the Beagle and as per his namesake, the Heron. He is also passionate about spending time outdoors and as such loves spending his summers surfing.
Example portfolio companies
We invest early stage (seed+ and series A) in businesses addressing large problems in human health (healthcare, life sciences and nutrition). Examples of our portfolio companies are:
Synthace: developing an operating system for laboratories to speed up drug discovery.
Oxford VR: using virtual reality therapies for mental health conditions.
Mahana: digital therapeutics for gastrointestinal conditions
Hadean: cloud first operating system enabling simulations at massive scale.
Phenomic: AI powered drug discovery.